ArticleFrontiers in surgery2025
Safety and efficacy of the HilumDirect uVATS for small cell lung cancer: a retrospective study.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Intestinal Obstruction Caused by Dual-Component Metastasis From Combined Small Cell Lung Cancer: A Rare Case and Literature Review.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advancements in multidisciplinary treatments, long-term survival rates for small cell lung cancer (SCLC) patients remain poor, and the role of surgical resection has been debated since the late 20th century. A more comprehensive surgical approach is necessary to enhance local control and improve outcomes. Method: The records of the patients who received surgical treatment between January 2015 and December 2020 were collected and analyzed with propensity-score matching. The preoperative characteristics, short-term outcomes, and long-term survival were analyzed and compared between the HilumDirect uVATS and the conventional uVATS groups. Results: Preoperative variables were well-balanced between the two groups. The HilumDirect uVATS group showed a numerically higher lymph node yield. Patients in the HilumDirect uVATS group pointed toward a numerical difference in cancer-specific survival (CSS) and recurrence-free survival (RFS) compared to the Conventional resection group (CSS, 50.82% vs. 44.09%, Conclusion: The HilumDirect uVATS resection can be safely performed by experienced surgeons with minimal invasiveness. Our findings suggest that selected SCLC patients, particularly those with positive lymph nodes, may benefit from this approach. However, further studies are warranted to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.